Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05207865 · ClinicalTrials.gov registry record · Phase 4
Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 441
- Enrollment target
NCT05207865: Completed Phase 4 study, sponsored by Pfizer.
NCT05207865 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 441 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (15% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05207865, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 441 participants
- Enrollment target
Study Summary
The purpose of this study is to further evaluate the long-term safety and tolerability of daily dosing of rimegepant for the prevention of episodic migraine.
Primary Outcome
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered an investigational (medicinal) product and did not necessarily have causal relationship with treatment. On-treatment AEs were those AEs which occurred after the study treatment start date until 7 days after last dose of study treatment. AEs were classified according to intensity as: mild: transient and required minimal treatment or therape
Interventions
- DRUG Rimegepant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 441 participants |
| Start Date | 2022-03-15 |
| Est. Completion | 2024-07-02 |
| Phase | Phase 4 |
What the finished NCT05207865 record still lists
NCT05207865 is an interventional study that assigns participants to a tested intervention. The registered 441 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (15% lower).
The record links to 0 conditions, and to 1 intervention - of which Rimegepant is the first listed.
NCT05207865 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05207865 about?
NCT05207865 is a clinical study titled "Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention". The purpose of this study is to further evaluate the long-term safety and tolerability of daily dosing of rimegepant for the prevention of episodic migraine.
What is the current status of trial NCT05207865?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 441 participants. The study started on 2022-03-15. Estimated completion is 2024-07-02.
What interventions are being tested in trial NCT05207865?
The interventions under investigation include: Rimegepant (DRUG).
Who is sponsoring clinical trial NCT05207865?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05207865's enrollment target sits among peer trials
441 190th of 2000 higher than 1,811 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02679144 · 441 participants · Phase 2
Neuroblastoma Maintenance Therapy Trial
- NCT03704766 · 442 participants · NA
Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis
- NCT04657068 · 442 participants · Phase 1
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- NCT05410145 · 442 participants · Phase 1
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI